103 Views | 45 Downloads
Sherryl H. Goodman, Department of Psychology, 36 Eagle Row, Emory University, Atlanta, GA 30322. Email: psysg@emory.edu
This material is based upon work supported by the National Science Foundation Graduate Research Fellowship Program under Grant No. DGE-1937971 and by the National Institute of Mental Health (K01 MH112876) and National Institute of Mental Health (1 P50 MH077928-01A1).
Authors Cochran, Pingeton, Goodman, and Laurent have no conflicts of interest to disclose. Dr. Rathouz has a regular appointment on a Data Safety Board for Sunovion Pharmaceuticals. Dr. Newport has received research support from Eli Lilly, Glaxo SmithKline (GSK), Janssen, the National Alliance for Research on Schizophrenia and Depression (NARSAD), the National Institutes of Health (NIH), SAGE, Takeda Pharmaceuticals, the Texas Health & Human Services Commission, and Wyeth. He has served on speakers’ bureaus and/or received honoraria from Astra-Zeneca, Eli Lilly, GSK, Pfizer and Wyeth. He has served on advisory boards for GSK, Janssen, and Sage Therapeutics. He has never served as a consultant to any biomedical or pharmaceutical corporations. Neither he nor family members have ever held equity positions in biomedical or pharmaceutical corporations. Dr. Stowe has received research support from NIH, CDC, GSK, Pfizer, Wyeth, Janssen and SAGE; has served on speaker or advisory boards for Pfizer, Eli Lilly, Wyeth, SAGE, BMS, and GSK; and has received honoraria from Eli Lilly, GSK, Pfizer, and Wyeth.